共 50 条
Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma
被引:2
|作者:
Bajestani, Nojan
[1
]
Wu, Gavin
[1
]
Hussein, Ahmed
[1
]
Makary, Mina S.
[2
]
机构:
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词:
hepatocellular carcinoma;
locoregional therapy;
immunotherapy;
combination therapy;
progression-free survival;
overall survival;
PERCUTANEOUS RADIOFREQUENCY ABLATION;
INTERNAL RADIATION-THERAPY;
RANDOMIZED CONTROLLED-TRIAL;
TRANSARTERIAL CHEMOEMBOLIZATION;
OPEN-LABEL;
PHASE-III;
SURGICAL RESECTION;
MICROWAVE ABLATION;
Y-90;
MICROSPHERES;
SYSTEMIC THERAPY;
D O I:
10.3390/biomedicines12071432
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文